CD4 and tuberculosis: Additional strong biomedical risk factors in adjusted analysis were active TB at ARV treatment initiation (IRR: 3.4, 95% CI: 1.7–7.1) and low CD4 percentage at enrollment (IRR per 10% increase: 0.5, 95% CI: 0.3–0.8).